每经记者｜闫峰峰 每经编辑｜吴永久 近日，奥康国际一名重要股东再次发布最高减持3%公司股份的计划，而在12月初该名股东刚实施完一 次减持计划。值得注意的是，此前，奥康国际股价经历了一轮显著的上涨行情，在短短4个月时间最大 涨幅近150%。不过奥康国际近三年持续亏损，那么，在连续亏损之下，奥康国际为何还能走出较为显 著的上涨行情？对此，每经资本眼专栏记者展开了调查。 重要股东连续减持，股价4个月涨幅近150%业绩却持续亏损 2025年12月9日，奥康国际公告称，公司持股5%以上股东项今羽计划通过集中竞价和大宗交易方式减持 不超过1200万股（占公司总股本3%）。此次减持前，项今羽持股占公司总股本比例为7.14%。 虽然，公司股价自8月高点以来总体处于调整态势，不过公司股价在形态上表现出相对高位横盘的态 势，当前公司股价仍处于相对高位。截至12月10日，奥康国际收盘价报收8.98元，较4月份的低点仍有 较大涨幅。 不过，在公司股价大幅上涨的同时，公司的业绩却身陷泥潭。同花顺数据显示，2022年至2024年，公司 分别实现营业收入27.54亿元、30.86亿元、25.39亿元，同比增速分别为-6.91%、12.05 ...

Group 1 - The company announced on July 11 that its controlling shareholder and actual controller, Wang Zhentao, is planning a change in control, which may lead to a change in the company's controlling shareholder and actual controller [1] - The specific plan for the change is still under consideration, and no agreements have been signed yet, with discussions ongoing regarding the transaction [1][4] - To ensure fair information disclosure and avoid abnormal stock price fluctuations, the company applied for a trading suspension starting July 14, expected to last no more than two trading days [4] Group 2 - On July 11, the company's stock opened lower but closed up significantly by 16.2%, with a closing price of 72.01 yuan per share and a total trading volume of 1.08 billion yuan, indicating a notable increase in trading activity compared to the average turnover rate of 2.94% over the previous 30 trading days [4] - The company primarily engages in the research, production, and sales of human vaccines, having obtained registration certificates for vaccines such as the freeze-dried human rabies vaccine and the ACYW135 group meningococcal polysaccharide vaccine [4] - Wang Zhentao, known as the "Shoe King" of Wenzhou, has faced significant pressure on the company's performance, with a reported net profit decline of over 80% year-on-year in the first quarter [5] Group 3 - In the first quarter, the company reported revenue of approximately 138 million yuan, a decrease of 55.7% year-on-year, and a net profit attributable to shareholders of approximately 20.71 million yuan, down 86.15% year-on-year [5] - The company's revenue has declined for three consecutive years, with projected revenues of approximately 1.447 billion yuan, 1.577 billion yuan, and 1.432 billion yuan for 2022, 2023, and 2024, respectively [5] - The overall vaccine industry is facing pressure, with many companies experiencing revenue and profit declines, necessitating adjustments in business strategies to cope with market competition and innovation challenges [5]